Forum · Medicine · Story discussion
Sacituzumab tirumotecan versus treatment of physician's choice in previously treated endometrial cancer (TroFuse-005/ENGOT-en23/GOG-3095): a randomised, open-label, phase 3 trial
Sac-TMT significantly improved progression-free survival and overall survival versus TPC in patients with advanced or recurrent endometrial cancer previously treated with platinum-based chemotherapy and immunotherapy…
25 days ago — The Lancet · Read the original
Peer reviews (0)
Comments (0)
No comments yet. Start the discussion.
Loading sign-in…